https://www.nasdaq.com/press-release/acer-therapeutics-to-participate-in-january-2022-virtual-investor-conferences-2021-12
https://www.nasdaq.com/press-release/acer-therapeutics-announces-acer-801-ind-clearance-for-the-treatment-of-induced
https://www.nasdaq.com/press-release/acer-therapeutics-reports-q3-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/acer-therapeutics-and-relief-therapeutics-announce-issuance-of-u.s.-patent-11154521
https://www.nasdaq.com/press-release/acer-therapeutics-receives-notice-of-allowance-of-key-u.s.-patent-application
https://www.nasdaq.com/press-release/acer-therapeutics-and-relief-therapeutics-announce-fda-acceptance-for-filing-of-new
https://www.nasdaq.com/press-release/acer-therapeutics-to-participate-in-h.c.-wainwright-23rd-annual-global-investment
https://www.nasdaq.com/press-release/acer-therapeutics-reports-q2-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/acer-therapeutics-and-relief-therapeutics-announce-submission-of-a-new-drug
https://www.nasdaq.com/press-release/relief-therapeutics-holdings-ag%3a-acer-therapeutics-and-relief-therapeutics-announce
https://www.nasdaq.com/press-release/50-companies-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-0
https://www.nasdaq.com/press-release/50-companies-to-present-at-the-access-to-giving-virtual-investor-conference-on-july
https://www.nasdaq.com/press-release/acer-therapeutics-plans-clinical-trial-for-edsivotm-celiprolol-following-type-b-fda
https://www.nasdaq.com/press-release/acer-therapeutics-plans-nda-submission-for-acer-001-in-q3-2021-following-pre-nda
https://www.nasdaq.com/press-release/acer-therapeutics-reports-q1-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/acer-therapeutics-to-participate-in-needham-virtual-healthcare-conference-2021-03-29
https://www.nasdaq.com/press-release/notice-of-settlement-of-derivative-suits-2021-03-25
https://www.nasdaq.com/press-release/relief-and-acer-therapeutics-sign-collaboration-and-license-agreement-for-worldwide
https://www.nasdaq.com/press-release/acer-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/acer-therapeutics-to-participate-in-march-virtual-investor-conferences-2021-03-01
https://www.nasdaq.com/press-release/acer-therapeutics-announces-topline-results-from-its-bioequivalence-trial-of-acer-001
https://www.nasdaq.com/press-release/acer-therapeutics-announces-full-enrollment-of-pivotal-bioequivalence-trial-of-acer
https://www.nasdaq.com/press-release/acer-therapeutics-announces-publication-of-vascular-ehlers-danlos-syndrome-veds
https://www.nasdaq.com/press-release/acer-therapeutics-reports-third-quarter-2020-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/acer-therapeutics-to-present-at-the-virtual-bio-investor-forum-digital-2020-10-01
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/acer-therapeutics-to-virtually-present-at-upcoming-investor-conferences-2020-08-25
https://www.nasdaq.com/press-release/acer-therapeutics-reports-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/ld-micro-announces-preliminary-list-of-presenters-for-the-ld-500-2020-08-05
https://www.nasdaq.com/press-release/acer-therapeutics-announces-administration-of-acer-001-in-a-fasted-state-increased
https://www.nasdaq.com/press-release/acer-therapeutics-reports-first-quarter-2020-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration
https://www.nasdaq.com/press-release/acer-therapeutics-announces-common-stock-purchase-agreement-for-up-to-%2415-million
https://www.nasdaq.com/press-release/acer-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/acer-receives-formal-dispute-resolution-request-fdrr-response-from-fdas-office-of-new
https://www.nasdaq.com/press-release/acer-therapeutics-announces-acer-001-for-urea-cycle-disorders-trial-shows
https://www.nasdaq.com/press-release/acer-therapeutics-announces-full-enrollment-of-part-b-in-acer-001-pivotal
https://www.nasdaq.com/press-release/acer-therapeutics-reports-third-quarter-2019-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/acer-therapeutics-announces-full-enrollment-of-part-a-in-acer-001-pivotal
https://www.nasdaq.com/press-release/acer-imminent-deadline%3a-rosen-a-top-ranked-law-firm-announces-filing-of-securities
https://www.nasdaq.com/press-release/final-deadline-acer-therapeutics-inc.-acer-bronstein-gewirtz-grossman-llc-reminds
https://www.nasdaq.com/press-release/lead-plaintiff-deadline%3a-johnson-fistel-llp-encourages-investors-to-contact-the-firm
https://www.nasdaq.com/press-release/lifshitz-miller-llp-announces-investigation-of-acer-therapeutics-inc.-aclaris
https://www.nasdaq.com/press-release/shareholder-alert%3a-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-14
https://www.nasdaq.com/press-release/kessler-topaz-meltzer-check-llp%3a-securities-fraud-class-action-filed-against-acer
https://www.nasdaq.com/press-release/lead-plaintiff-deadline-alert%3a-faruqi-faruqi-llp-encourages-investors-who-suffered-16
https://www.nasdaq.com/press-release/wedbush-securities-senior-vice-president-equity-research-laura-chico-ph.d.-initiates
https://www.nasdaq.com/press-release/acer-therapeutics-participate-upcoming-investor-conferences-2019-04-21-0
